2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N9541
    Chaetoglobosin Vb 1399690-75-5 98%
    Chaetoglobosin Vb is a novel cytotoxic alkaloid with anti-inflammatory and antioxidant activities. Chaetoglobosin Vb can inhibit oxidative stress induced by LPS stimulation, reduce the production of reactive oxygen species and increase the expression of the antioxidant enzyme superoxide dismutase (SOD). Chaetoglobosin Vb significantly reduced the gene and protein expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) induced by LPS, and alleviated the production of proinflammatory cytokines such as TNF-α, IL-6 and IL-1β. Chaetoglobosin Vb exerts its biological activity through the TLR4-mediated MyD88-dependent signaling pathway and the TRIF-dependent signaling pathway, which is specifically manifested by inhibiting the phosphorylation of p38, ERK, and JNK MAPK and the translocation of NF-κB p65 subunit to the nucleus. Chaetoglobosin Vb showed no cytotoxic effect in the concentration range of 25-100 μM and promoted SOD enzyme activity and phosphorylation of p38, ERK1/2 and JNK in a dose-dependent manner.
    Chaetoglobosin Vb
  • HY-N9866
    Grasshopper ketone 41703-38-2 98%
    It is a bioactive compound with anti-inflammatory activity that inhibits LPS-induced NO production in RAW 264.7 cells and acts by inhibiting the phosphorylation of MAPK (ERK, JNK and p38) and NF-κB p65. Grasshopper ketone, as an ingredient, has shown its potential in anti-inflammatory inhibition.
    Grasshopper ketone
  • HY-N9953
    Chrysophanol 8-O-β-D-(6′-O-galloyl)glucopyranoside 266997-57-3 98%
    Chrysophanol 8-O-β-D-(6’-O-galloyl)glucopyranoside, an anthraquinone glucoside, can be isolated from Rheum undulatum L. Chrysophanol 8-O-β-D-(6’-O-galloyl)glucopyranoside has potent DPPH radical and ?O2- scavenging activity.
    Chrysophanol 8-O-β-D-(6′-O-galloyl)glucopyranoside
  • HY-N9987
    11β,13-Dihydrolactucin 83117-63-9 98%
    11β,13-Dihydrolactucin is an antimicrobial agent. 11β,13-Dihydrolactucin also has several biological properties, including antioxidant, anti-inflammatory, and antitumor activities.
    11β,13-Dihydrolactucin
  • HY-P1355
    Cyclosporin A-Derivative 1 1487360-85-9 98%
    Cyclosporin A-Derivative 1 is a crystalline intermediate derived from the opening of cyclosporin A extracted from patent WO 2013167703 A1. Cyclosporin A is an immunosuppressive agent which can bind to the cyclophilin and inhibit calcineurin.
    Cyclosporin A-Derivative 1
  • HY-P1409
    ADWX 1 98%
    ADWX 1 is a new peptide inhibitor that is potent and selective for Kv1.3 with an IC50 value of 1.89 pM. ADWX 1 inhibits Kv1.3 channel activity specifically to inhibit both the initial calcium signaling and NF-κB activation. ADWX 1 ameliorates the disease in rats of experimental autoimmune encephalomyelitis (EAE) models. ADWX 1 can be used to study T cell-mediated autoimmune diseases.
    ADWX 1
  • HY-P2033
    Nostopeptin B 185980-89-6 98%
    Nostopeptin B is a cyclic dipeptide that can be isolated from N. minutum (NIES-26). The structure of Nostopeptin B contains Ahp (3-amino-6-hydroxy-2-piperidone), which exhibits effective inhibition against elastase and chymotrypsin.
    Nostopeptin B
  • HY-P3199
    PKCβII Peptide Inhibitor I 862502-26-9 98%
    PKCβII Peptide Inhibitor I is a PKCβII inhibitor. PKCβII Peptide Inhibitor I shows cardioprotective effects in rat cardiac Ischemia/reperfusion injury model. PKCβII Peptide Inhibitor I also prevents vascular endothelial dysfunction.
    PKCβII Peptide Inhibitor I
  • HY-P5551
    TLN-58 98%
    TLN-58 is an antimicrobial peptide. TLN-58 has antibacterial activity against S. aureus, S. epidermidis, and group A Streptococcus. TLN-58 also induces inflammatory cytokine mRNAs upregulation in normal human keratinocytes and NCL-SG3 cells.
    TLN-58
  • HY-Z3707
    N3-Methyl pantoprazole 721924-06-7 98%
    N3-Methyl pantoprazole is an impurity of Pantoprazole (HY-17507).
    N3-Methyl pantoprazole
  • HY-Z6663
    Salbutamol methyl ether 870076-72-5 98%
    Salbutamol methyl ether is a derivative of Salbutamol (HY-B1037) used as an immunohapten to obtain antibodies.
    Salbutamol methyl ether
  • HY-Z7640
    4-Desmethyl-2-methyl celecoxib 170569-99-0 98%
    4-Desmethyl-2-methyl celecoxib (Compound 1g) is an orally active and selective Cyclooxygenase-2 (COX-2) inhibitor with an IC50 value of 0.069 μM. 4-Desmethyl-2-methyl celecoxib shows anti-inflammatory, analgesic, and antipyretic activities. 4-Desmethyl-2-methyl celecoxib can reduces the synthesis of prostaglandins. 4-Desmethyl-2-methyl celecoxib is promising for research of inflammatory diseases and pain-related diseases, such as rheumatoid arthritis and osteoarthritis.
    4-Desmethyl-2-methyl celecoxib
  • HY-Z7659
    Lansoprazole sulfone N-Oxide 953787-54-7 98%
    Lansoprazole sulfone N-Oxide (Comound 3) is the overoxidized by-product found in the synthesis of the proton pump inhibitor Lansoprazole (HY-13662). Lansoprazole sulfone N-Oxide is promising for research of duodenal and gastric ulcers, reflux oesophagitis, and Zollinger–Ellison syndrome.
    Lansoprazole sulfone N-Oxide
  • HY-Z7660
    Lansoprazole N-oxide 213476-12-1 98%
    Lansoprazole N-oxide (Comound 2) is the overoxidized by-product found in the synthesis of the proton pump inhibitor Lansoprazole (HY-13662). Lansoprazole N-oxide is promising for research of duodenal and gastric ulcers, reflux oesophagitis, and Zollinger–Ellison syndrome.
    Lansoprazole N-oxide
  • HY-Z8025
    Deprodone 20423-99-8 98%
    Deprodone is an active compound. Deprodone inhibits key processes such as bacterial cell wall synthesis by interacting with the hydrolase and transferase proteins of methicillin-resistant Staphylococcus aureus (MRSA). Deprodone is used in research on anti-MRSA infection, inflammatory skin disorders, bowel disease, and fatty acid metabolism disorders.
    Deprodone
  • HY-Z8648
    Δ14-Triamcinolone acetonide 1260149-96-9 98%
    Δ14-Triamcinolone acetonide is a potential impurity. Triamcinolone acetonide inhibits basic fibroblast growth factor (bFGF) induced proliferation of retinal endothelial cells. Triamcinolone acetonide reduces chondrocyte viability and leads to cartilage destruction. Triamcinolone acetonide can be used in the study of diseases such as atopic dermatitis.
    Δ14-Triamcinolone acetonide
  • HY-100153
    48740 RP 93363-11-2 98%
    48740 RP ((Rac)-RP-55778) is a platelet-activating factor (PAF) antagonist.
    48740 RP
  • HY-10015R
    PAP-1 (Standard) 870653-45-5 98%
    PAP-1 (Standard) is the analytical standard of PAP-1. This product is intended for research and analytical applications. PAP-1 (5-(4-Phenoxybutoxy)psoralen) is a potent, selective, and orally active Kv1.3 blocker (EC50=2 nM). PAP-1 blocks Kv1.3 in a use-dependent manner and acts by preferentially binding to the C-type inactivated state of the channel. PAP-1 exhibits 23-fold selectivity over Kv1.5 (EC50=45 nM), and further displays 33- to 125-fold selectivity over all other Kv1-family channels. PAP-1 does not exhibit cytotoxic or phototoxic effects.
    PAP-1 (Standard)
  • HY-10019R
    Varenicline (Standard) 249296-44-4 98%
    Varenicline (Standard) is the analytical standard of Varenicline. This product is intended for research and analytical applications. Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α7β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation.
    Varenicline (Standard)
  • HY-10020R
    Varenicline Hydrochloride (Standard) 230615-23-3 98%
    Varenicline (Hydrochloride) (Standard) is the analytical standard of Varenicline (Hydrochloride). This product is intended for research and analytical applications. Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC50 = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α6β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation.
    Varenicline Hydrochloride (Standard)
Cat. No. Product Name / Synonyms Application Reactivity